Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–22. https://doi.org/10.1038/s41591-018-0104-9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2018;15(7):425–39. https://doi.org/10.1038/s41575-018-0010-0.
Article
PubMed
Google Scholar
Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138–53. https://doi.org/10.1136/gutjnl-2017-313884.
Article
PubMed
Google Scholar
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. https://doi.org/10.1002/hep.28431.
Article
PubMed
Google Scholar
Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14(1):32–42. https://doi.org/10.1038/nrgastro.2016.147.
Article
CAS
PubMed
Google Scholar
Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124–31. https://doi.org/10.1053/j.gastro.2010.09.038.
Article
PubMed
Google Scholar
Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, Qiu Y, Burns L, Afendy A, Nader F. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801. https://doi.org/10.1016/j.jhep.2019.06.021.
Article
PubMed
Google Scholar
Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S, Bendtsen F. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–97 e310. https://doi.org/10.1053/j.gastro.2015.04.043.
Article
PubMed
PubMed Central
Google Scholar
Hagstrom H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265–73. https://doi.org/10.1016/j.jhep.2017.07.027.
Article
PubMed
Google Scholar
Bian H, Zhu X, Xia M, Yan H, Chang X, Hu X, Pan B, Guo W, Li X, Gao X. Impact of type 2 diabetes on nonalcoholic steatohepatitis and advanced fibrosis in patients with nonalcoholic fatty liver disease. Endocr Pract. 2020;26(4):444–53. https://doi.org/10.4158/EP-2019-0342.
Article
PubMed
Google Scholar
Bhati C, Idowu MO, Sanyal AJ, Rivera M, Driscoll C, Stravitz RT, Kohli DR, Matherly S, Puri P, Gilles HC, Cotterell A, Levy M, Sterling RK, Luketic VA, Lee H, Sharma A, Siddiqui MS. Long-term outcomes in patients undergoing liver transplantation for nonalcoholic Steatohepatitis-related cirrhosis. Transplantation. 2017;101(8):1867–74. https://doi.org/10.1097/TP.0000000000001709.
Article
PubMed
Google Scholar
Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, Sebastiani G, Ekstedt M, Hagstrom H, Nasr P, Stal P, Wong VWS, Kechagias S, Hultcrantz R, Loomba R. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65(5):1557–65. https://doi.org/10.1002/hep.29085.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38(6):1449–57. https://doi.org/10.1053/jhep.2003.09022.
Article
PubMed
Google Scholar
Gaidos JKJ, Hillner BE, Sanyal AJ. A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis. Liver Int. 2008;28(5):650–8. https://doi.org/10.1111/j.1478-3231.2008.01693.x.
Article
PubMed
Google Scholar
Bravo AA. Sheth Sg Fau - Chopra S, Chopra S. Liver biopsy N Engl J Med. 2001;344(7):495–500. https://doi.org/10.1056/NEJM200102153440706.
Article
CAS
PubMed
Google Scholar
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57. https://doi.org/10.1002/hep.29367.
Article
PubMed
Google Scholar
Baumeler S, Jochum W, Neuweiler J, Bergamin I, Semela D. Controlled attenuation parameter for the assessment of liver steatosis in comparison with liver histology: a single-Centre real life experience. Swiss Med Wkly. 2019;149:w20077.
PubMed
Google Scholar
Imajo K, Kessoku T, Honda Y, Tomeno W, Ogawa Y, Mawatari H, Fujita K, Yoneda M, Taguri M, Hyogo H, Sumida Y, Ono M, Eguchi Y, Inoue T, Yamanaka T, Wada K, Saito S, Nakajima A. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology. 2016;150(3):626–37 e627. https://doi.org/10.1053/j.gastro.2015.11.048.
Article
PubMed
Google Scholar
Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S. Transient elastography (FibroScan((R))) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - where do we stand? World J Gastroenterol. 2016;22(32):7236–51. https://doi.org/10.3748/wjg.v22.i32.7236.
Article
PubMed
PubMed Central
Google Scholar
Shen F, Zheng RD, Mi YQ, Fan JG, Mi YQ, Lédinghen V, et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World J Gastroenterol. 2014;20(16):4702–11. https://doi.org/10.3748/wjg.v20.i16.4702.
Article
PubMed
PubMed Central
Google Scholar
Jung KS, Kim SU, Ahn SH, Park YN, Kim DY, Park JY, Chon CY, Choi EH, Han KH. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology. 2011;53(3):885–94. https://doi.org/10.1002/hep.24121.
Article
CAS
PubMed
Google Scholar
Tapper EB, Challies T, Nasser I, Afdhal NH, Lai M. The performance of vibration controlled transient elastography in a US cohort of patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2016;111(5):677–84. https://doi.org/10.1038/ajg.2016.49.
Article
CAS
PubMed
PubMed Central
Google Scholar
Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Guha IN, Cobbold JF, Deeks JJ, Paradis V, Bedossa P, Newsome PN. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717–30. https://doi.org/10.1053/j.gastro.2019.01.042.
Article
PubMed
Google Scholar
Chinese Foundation for Hepatitis Prevention and Control; Chinese Society of Infectious Disease and Chinese Society of Hepatology, Chinese Medical Association; Liver Disease Committee of Chinese Research Hospital Association. Consensus on clinical application of transient elastography detecting liver fibrosis: a 2018 update. Chin J Hepatol. 2019;27:182–91.
Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21. https://doi.org/10.1002/hep.20701.
Article
PubMed
Google Scholar
Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR, NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–85. https://doi.org/10.1056/NEJMoa0907929.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M, Palau R. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29(12):1705–13. https://doi.org/10.1016/j.ultrasmedbio.2003.07.001.
Article
PubMed
Google Scholar
Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, Wainford RD, Williams B, Schutte AE. 2020 international society of hypertension global hypertension practice guidelines. J Hypertens. 2020;38(6):982–1004. https://doi.org/10.1097/HJH.0000000000002453.
Article
CAS
PubMed
Google Scholar
Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20(7):1183–97. https://doi.org/10.2337/diacare.20.7.1183.
Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P, Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Expert committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26(11):3160–7. https://doi.org/10.2337/diacare.26.11.3160.
Article
PubMed
Google Scholar
Zeng X, Xu C, He D, Zhang H, Xia J, Shi D, Kong L, He X, Wang Y. Influence of hepatic inflammation on fibroScan findings in diagnosing fibrosis in patients with chronic hepatitis B. Ultrasound Med Biol. 2015;41(6):1538–44. https://doi.org/10.1016/j.ultrasmedbio.2015.01.011.
Article
PubMed
Google Scholar
Wong GL, Wong VW, Chim AM, Yiu KK, Chu SH, Li,MK, et al. Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population. J Gastroenterol Hepatol 2011;26:300–305, 2, DOI: https://doi.org/10.1111/j.1440-1746.2010.06510.x.
Shen F, Zheng RD, Shi JP, Mi YQ, Chen GF, Hu X, Liu YG, Wang XY, Pan Q, Chen GY, Chen JN, Xu L, Zhang RN, Xu LM, Fan JG. Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease. Liver Int. 2015;35(11):2392–400. https://doi.org/10.1111/liv.12809.
Article
PubMed
PubMed Central
Google Scholar